Direct NMD inhibition using small-molecule inhibitors (e.g., NMDI-1 [76], CC-115 [156]) or genetic suppression of NMD factors (e.g., UPF1 knockdown [133]) can restore the expression of TSGs or enhance tumor antigenicity. The gene discussed is PLA1A; the disease is neoplasm.